Design and Application of Conjugatable Small Molecule Toll-Like Receptor 4 Ligands

Area of Science:

• Medicinal Chemistry
• Immunology
• Nanotechnology

Background:

• Pyrimido[5,4-b]indole derivatives have shown potential as toll-like receptor 4 (TLR4) ligands.
• Structure-activity relationship studies indicated that C8-aryl substitutions enhance TLR4 activation.
• Molecular modeling suggested the N5 position as a viable site for drug conjugation.

Purpose of the Study:

• To investigate the N5 position of pyrimido[5,4-b]indole for conjugation without compromising TLR4 ligand potency.
• To synthesize and evaluate novel TLR4 ligands with modifications at the N5 and C8 positions.
• To develop TLR4 ligand-nanoparticle conjugates for enhanced immunomodulatory applications.

Main Methods:

• In silico molecular docking analysis to predict binding of tetraethylene glycol (TEG) derivatives at the N5 position.
• Synthesis of pyrimido[5,4-b]indole derivatives with TEG groups at N5 and various C8 substitutions.
• Evaluation of immunostimulatory activity using human TLR4 reporter cell assays and primary murine bone marrow dendritic cells (mBMDCs).
• Conjugation of a potent TLR4 ligand (TLR4L 10) to sugar-immobilized gold nanoparticles (SGNPs) via a thioctic acid spacer.

Main Results:

• The N5 position was successfully utilized for conjugation with TEG moieties without loss of TLR4 binding affinity.
• TLR4 ligand 10, featuring a 3-thienylethynyl group at C8, maintained significant TLR4 potency and agonistic activity.
• TLR4L-SGNP conjugate 17 demonstrated uptake and retained agonistic activity in mBMDCs.

Conclusions:

• Novel pyrimido[5,4-b]indole derivatives with modifications at C8 and N5 positions are potent TLR4 ligands.
• The designed TLR4L 10 and its nanoparticle conjugate TLR4L-SGNP 17 represent promising candidates for immunomodulators.
• These compounds hold potential for use in novel adjuvant systems for enhanced immune responses.